Premium
Evidence of predisposing epimutation in retinoblastoma
Author(s) -
Gelli Elisa,
Pinto Anna Maria,
Somma Serena,
Imperatore Valentina,
Can Marta G.,
Hadjistilianou Theodora,
Francesco Sonia,
Galimberti Daniela,
Currò Aurora,
Bruttini Mirella,
Mari Francesca,
Renieri Alessandra,
Ariani Francesca
Publication year - 2019
Publication title -
human mutation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 162
eISSN - 1098-1004
pISSN - 1059-7794
DOI - 10.1002/humu.23684
Subject(s) - biology , dna methylation , methylation , cpg site , germline , genetics , germline mutation , retinoblastoma , epigenetics , microbiology and biotechnology , cancer research , bisulfite sequencing , gene , mutation , gene expression
Retinoblastoma (RB), which represents the most common childhood eye cancer, is caused by biallelic inactivation of RB1 gene. Promoter hypermethylation is quite frequent in RB tissues but conclusive evidence of soma‐wide predisposing epimutations is currently scant. Here, 50 patients who tested negative for RB1 germline sequence alterations were screened for aberrant promoter methylation using methylation‐specific MLPA. The assay, performed on blood, identified a sporadic patient with methylation of CpG106, absent in parents’ DNA. Bisulfite pyrosequencing accurately quantified CpG methylation in blood DNA (mean ∼49%) and also confirmed the aberration in DNA isolated from oral mucosa although at lower levels (mean ∼34%). Using a tag‐SNP, methylation was demonstrated to affect the maternal allele. Real‐time qPCR demonstrated RB1 transcriptional silencing. In conclusion, we documented that promoter methylation can act as the first “hit” in Knudson's model. This mosaic epimutation mimics the effect of an inactivating mutation and phenocopies RB onset.